Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482094 | 0.88 | FUCA1 (0.47) | FUCA1GLAENGASENPSR1CACNA1H | |
| SCHEMBL24133924 | 0.78 | FUCA1 (0.38) | FUCA1GLAENGASENPSR1CACNA1H | |
| SCHEMBL17249606 | 0.77 | — | — | |
| SCHEMBL30421032 | 0.76 | CA1 (0.47) | FUCA1GLAENGASEFAPDPP4 | |
| SCHEMBL21602026 | 0.74 | FUCA1 (0.40) | FUCA1GLAENGASENPSR1CACNA1H | |
| SCHEMBL13809942 | 0.74 | CYP2C9 (0.38) | FUCA1GLANPSR1CACNA1HFAP | |
| SCHEMBL13809941 | 0.74 | CYP2C9 (0.38) | FUCA1GLANPSR1CACNA1HFAP | |
| SCHEMBL1866565 | 0.73 | FUCA1 (0.40) | FUCA1GLAENGASENPSR1CACNA1H | |
| SCHEMBL25608119 | 0.72 | FUCA1 (0.37) | FUCA1GLAENGASENPSR1CACNA1H | |
| SCHEMBL10563256 | 0.71 | FUCA1 (0.51) | FUCA1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825313-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210047304-A1 | Bromodomain Inhibitors | ABBVIE INC. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047304-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | FUCA1 2712/4885GLA 1340/4885ENGASE 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.